Reports Q4 revenue $24.4M, consensus $21.76M. "The past year was a landmark for Axsome, which saw us bring our first fully in-house end-to-end developed drug to market, potentially transforming the treatment landscape for depression and providing the potential to improve the lives of millions of patients and their loved ones," said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. "With two differentiated products in Auvelity and Sunosi now commercialized, encouraging early launch metrics for Auvelity, a broad and advancing late-stage CNS pipeline, and a strong financial position, Axsome is well positioned to continue to deliver significant value to patients and shareholders. We are looking forward to another milestone filled year which has already kicked off with an important licensing agreement for Sunosi in Europe that serves to expand patient access to this important treatment while providing significant potential future value to Axsome. Over the next 12 to 18 months, we look to continuing to execute on the commercialization of Auvelity and Sunosi, initiating or reading out at least four registration trials in indications of high unmet need, and potentially filing four new NDAs."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXSM:
- Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Pharmanovia announces in-licensing agreement with Axsome for Sunosi
- Axsome Therapeutics enters license agreement with Pharmanovia
- Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
- Axsome facing Auvelity IP challenge ‘not a surprise,’ says BofA